Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

MarketBeat

Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading strategies.

Barchart

COVID Nimbus Explained: Key Symptoms, Warning Signs, and What You Need to Know

Get essential facts on COVID Nimbus (NB.1.8.1) symptoms, transmission, risk groups, prevention, and treatment to stay informed and protect your health.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

MarketBeat

Despite Trump pressure, Big Pharma is raising hundreds of drug prices

Costs of at least 350 branded medications, including vaccines against Covid-19, shingles and cancer treatment Ibrance, will reportedly be hiked

The Independent UK

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

MarketBeat

Stocks Chop as the Unemployment Rate Jumps: Stock Market Today

November job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

MarketBeat

Is there much COVID around? Do I need the new booster shot LP.8.1?

COVID rarely rates a mention in the news these days, yet it hasn’t gone away.

The Conversation

Trump’s FDA plans to put a ‘black box’ warning on COVID vaccines: report

Black boxes are the FDA’s most serious warning sign and are usually placed on opioid products

The Independent UK

This RFK Jr.-founded group demands the FDA kill the COVID vaccine

An anti-vaccine organization founded by Robert F. Kennedy Jr. filed a petition to remove the shots from the market.

Axios

Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.

International Business Times

Netflix officially buys Warner Bros., leaving Hollywood worried and Christopher Nolan scrambling to be its protector

This is only a good deal for the billionaires trying to buy a new yacht

We Got This Covered

New York’s empty office blocks being transformed into 12,000 new apartments

New York City office buildings that were originally used by firms such as Goldman Sachs are being transformed into luxury apartments

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Trump mocked by ‘Stocktwits’ X account after his claim that drug prices have fallen by ‘700%’

President boasted that drug prices were falling ‘700%’, a mathematical impossibility, as a result of his executive actions

Barchart

Is Pfizer Stock Underperforming the Dow?

While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.

Benzinga

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.

Benzinga

Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications, resulting in substantial annual savings on prescription expenses.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Simple Options Strategies to Act on Thursday’s Unusual Activity Now

Market volatility has ratcheted up in recent days. The S&P 500 was on course for its worst week in months before Friday’s open. These three strategies rely on Thursday’s unusual options activity for investors wanting to keep things simple.

Benzinga

Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

A Phase 3 study funded by Pfizer Inc. (NYSE:PFE) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential shift in how seasonal influenza is prevented.

Barchart

Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?

MarketBeat

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

The Texas Tribune

A small Texas think tank cultivated COVID dissidents. Now they’re running U.S. health policy.

People with ties to Brownstone Institute have significant authority over access to vaccines and scientific research.

Benzinga

Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market

Purdue Pharma won court approval to exit bankruptcy, ending six years of litigation over its multibillion-dollar opioid settlement and the Sackler family’s liability releases. Purdue's Chapter 11 plan provides an estimated $7.4 billion to address nationwide opioid harm.

Benzinga

Ozempic Maker Novo Nordisk Faces Board Shakeup

On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

1,604 stories

JPMorgan

1,321 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.